🧾 What This Document Is

This is Aspire Biopharma's 10-K annual report, the comprehensive yearly filing required by the SEC for public companies. It’s a deep dive into their business operations, financial performance, and the risks they face. Think of it as the company's official report card for the fiscal year ended December 31, 2025.

🏢 What The Company Does

👉 In simple terms, Aspire is a small, early-stage pharmaceutical company developing a patent-pending method to deliver drugs under the tongue (sublingually) for faster absorption into the bloodstream. Their star product is a high-dose aspirin powder aimed at treating heart attacks faster and avoiding stomach irritation.

They are a "smaller reporting company" and "emerging growth company," meaning they have limited revenue, are in the early stages of development, and have certain regulatory exemptions. The company was formerly a blank-check (SPAC) company called PowerUp Acquisition Corp. before merging with the actual biopharma business on February 17, 2025, in a "reverse recapitalization" (a fancy term for a SPAC merger).

🚀 Key Moves & Recent Developments

This was a massive year of change and financing for the company.

• The SPAC Merger: The foundational event was the February 17, 2025, merger. For accounting purposes, the small biopharma company is considered the "acquirer," not the former shell company.
• Aggressive Financing: To fund operations, they issued several expensive convertible debt instruments:
  • $3.75M in Senior Secured Debentures (Feb 2025) to investors including an entity linked to their former Director of Investor Relations.
  • $9.69M in August 2025 Notes (Aug-Sep 2025) with a 20% discount. These have since been converted into stock.
• Nasdaq Compliance Drama: They received delisting notices in April 2025 for falling below the minimum market value and share price requirements. They fought for and were granted an extension to February 17, 2026, to regain compliance. They report having since met the share price and stockholders' equity rules.
• Settlement of Disputes: They entered a Settlement Agreement (April 24, 2025) with lenders (linked to the former Director) to resolve alleged defaults and extend debt maturities.

💊 Pipeline & Clinical Trials

This is the core of their potential future business.

• Aspirin (Lead Product):
  • Technology: A patent-pending sublingual powder/granule that aims to deliver aspirin faster into the bloodstream, bypassing the stomach.
  • Status: Completed a bioavailability study in July 2025 (final report received Sept 5, 2025). Results were positive, showing faster absorption than standard aspirin.
  • Next Step: Plans to run a new clinical trial (~32 volunteers) starting summer 2026 to prove it works faster for heart attack patients. Aims to submit a 505(b)(2) NDA to the FDA in 2026, leveraging aspirin's long history of safety.
• Other Products in Development:
  • Melatonin: Formulation complete (as a supplement, no FDA approval needed). Exploring licensing.
  • Caffeine ("Buzz Bomb"): Sold initial versions in Q3 2025; manufacturing 2 million units for sale starting Jan 15, 2026.
  • ED Medication, Vitamins, Anti-Nausea Drugs, etc.: Various early-stage formulations. Many have new patent applications filed.

📦 Financial Position & Challenges

The numbers tell the story of a pre-revenue company burning cash to develop its tech.

• Cash is King (and Scarce): As of December 31, 2025, they had $2.76 million in cash. They have a history of losses and expect to continue incurring them.
• Complex Financing: They rely heavily on equity lines of credit (ELOCs) and convertible debt, which can lead to significant shareholder dilution. For example, they have a $100 million ELOC agreement with Arena Business Solutions from November 2025.
• Debt Overhang: The report details numerous promissory notes and related party loans. While some have been converted or settled, the financing activities are complex and ongoing.
• Revenue: The company has no material revenue from product sales. Any income is likely from financing activities.

⚖️ Big Picture: Strengths & Risks

👍 Strengths:

• Novel Delivery Technology: Their sublingual method is a genuine differentiator, especially for drugs where speed or stomach avoidance is critical.
• Established Drug Foundation: Building on aspirin, a drug with over 100 years of safety data, is a smart strategic shortcut.
• Active IP Portfolio: They have multiple new patent applications filed to protect their formulations.

⚠️ Significant Risks:

• Need for Capital: They have a history of net losses and will need substantially more cash to fund clinical trials and commercialization. They may not be able to raise it.
• Regulatory Hurdles: There is no guarantee the FDA will approve their sublingual aspirin product, even with a 505(b)(2) pathway.
• History of Compliance Issues: The Nasdaq delisting threat and disputes with lenders highlight operational and financial risks.
• Dilution: Future fundraising will likely involve issuing more shares, reducing the value of existing shares.
• Competition: They face massive competitors with far more resources (e.g., Bayer, Pfizer).

🧠 The Analogy

Think of Aspire as a company with a really promising new engine (the sublingual tech) that they're trying to build into a race car (a commercial drug). The 10-K shows they've spent the year securing a garage (the SPAC merger), buying parts with borrowed money (aggressive debt financing), and running initial engine tests (clinical trials). They're not on the racetrack yet, and the car isn't even fully assembled. The big question is whether they can raise enough fuel (cash) to finish building it and get to the starting line without the whole project stalling.

📇 Key Contacts & People

• Principal Executive Offices: 23150 Fashion Dr., Suite 232, Estero, FL 33928
• Registrant’s telephone number: (908) 987-3002
• Auditor: Turner, Stone and Company, LLP
• Transfer Agent: Colonial Stock Transfer Co, Inc.
• Notable Parties in Transactions:
  • Cobra Alternative Capital Strategies, LLC (Investor)
  • Arena Business Solutions Global SPC II, Ltd. (ELOC Provider)
  • Blackstone Capital Advisors, Inc. (Consultant/Lender)
  • Lance Friedman (Former Director of Investor Relations, linked to several financing entities)

🧩 Final Takeaway

Aspire Biopharma is a high-risk, early-stage bet on a potentially disruptive drug delivery technology. The 2025 fiscal year was about survival and setup: completing the SPAC merger, conducting key aspirin studies, and securing expensive financing to keep the lights on. The path ahead is long, capital-intensive, and uncertain, hinging on successful clinical trials, FDA approval, and the ability to fund operations without drowning in debt or diluting shareholders into oblivion.